Contract manufacturing organisation (CMO) NextPharma Technologies has added Andrew Kelley, Pierre Delavaud and Matthew Wilder to its senior team.
Kelley has been appointed chief operating officer of the Surrey, UK-based firm; Delavaud (pictured) will take over as executive VP sales and marketing; and Matthew Wilder joins as VP of US sales and marketing.
The most experienced new employee is Kelley. He has spent more than 27 years in the pharma industry and was recently VP of business development Europe and Asia-Pacific at Canada-based CMO Patheon.
Previous positions have included VP of European operations at Catalent and manufacturing manager at Boehringer Ingelheim.
Andrew Kelley, Pierre Delavaud and Matthew Wilder
Delavaud joins NextPharma from SkyePharma where he had served as executive VP of sales and business development since September, 2011.
Prior to that he spent 14 years at Catalent serving in several senior positions, including VP of business development, global pharmaceutical softgel.
Wilder was most recently at Sanofi, where he had been for ten years, holding roles that included divisional sales manager and regional sales director.
Franck Latrille, NextPharma’s CEO, said: “We are delighted to welcome our three new colleagues to our growing team at NextPharma. This is an exciting time for the company, and we are confident that with the injection of their expertise to the team, we can continue to improve our business offerings.”